Adocia
Develops clinical-stage treatments for diabetes and obesity for patients with metabolic diseases
Highlights
- New on EvolcAdded 2026-10-29
About Adocia
Adocia is a French biotechnology company that discovers and develops therapeutic solutions for chronic metabolic diseases, particularly diabetes and obesity. Its products include formulations of approved peptides and proteins, as well as cell-therapy technologies.
The company licenses proprietary products to pharmaceutical companies after proof of concept and partners on its technology platforms. Its pipeline includes products in clinical trials from Phase 1 to Phase 3.
Adocia was founded in 2006 and is headquartered in Lyon, France. Its team includes more than 80 staff, with most employees dedicated to research and development.
Product: Clinical-stage therapeutic products and technology platforms for diabetes, obesity and other metabolic diseases.
Jobs at Adocia
More biotech & pharma companies
Adragos Pharma
Contract development and manufacturing for pharma and biotech clients in Europe, Japan and North AmericaAdvesya
Clinical-stage biotech developing IL-1RAP-targeted CAR T-cell and ADC treatments for cancer and autoimmune diseasesNew on EvolcAelis Farma
Develops CB1-targeted drug candidates for people with cannabis-related disorders and cognitive deficitsNew on EvolcAenitis Technologies
Acoustic levitation cell-handling devices and single-use consumables for cell and gene therapy bioprocessingNew on EvolcAffilogic
Develops Nanofitin-based therapeutics and custom binding proteins for pharmaceutical and biotech partnersNew on EvolcAffinisep
Sample preparation kits and SPE cartridges for analytical labs in proteomics, metabolomics, and water analysisNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Apache
- Bootstrap
- Complianz
- Google Analytics 4
- Google reCAPTCHA
- PHP
- WordPress
- jQuery